This trial is active, not recruiting.

Condition breast cancer
Treatments healthy controls, metastatic breast cancer, non-cancer medical illness
Sponsor University of California, Davis
Start date September 2006
End date February 2011
Trial size 200 participants
Trial identifier NCT00897962, CDR0000583066, UCD-186, UCD-200614601


RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur and identify biomarkers related to cancer.

PURPOSE: This research study is looking at blood glycan biomarkers in women with stage IV breast cancer.

United States No locations recruiting
Other countries No locations recruiting

Primary Outcomes

Profiling serum glycan biomarkers in patients with metastatic breast cancer, healthy controls, and patients with noncancer medical illness
time frame: up to 18 months

Secondary Outcomes

Predictability of serial serum biomarkers in determining disease response and/or progression
time frame: Up to 18 months

Eligibility Criteria

Female participants at least 18 years old.

DISEASE CHARACTERISTICS: - Patient or participant at the Women's Health Clinic, the Internal Medicine Clinic, or at the UC Davis Cancer Center, meeting 1 of the following criteria: - Diagnosis of stage IV metastatic breast cancer, receiving active treatment with chemotherapy, endocrine therapy, or targeted therapy - Patients/participants without cancer - Healthy control being seen for annual exams, meeting the following criteria: - No chronic disease - Not on regular prescribed medications - Patient without cancer being seen in the Internal Medicine Clinic - Hormone receptor status not specified PATIENT CHARACTERISTICS: - Menopausal status not specified - Not pregnant or breast feeding - No other active cancer PRIOR CONCURRENT THERAPY: - See Disease Characteristics

Additional Information

Official title Serum Glycan Analysis in Breast Cancer
Description OBJECTIVES: - To profile serum glycan biomarkers in women with metastatic stage IV breast cancer, healthy controls, and patients with noncancer medical illness. - To determine whether serial serum glycan biomarkers correlate with response of metastatic disease to treatment. OUTLINE: This is a multicenter study. Blood is collected from patients with metastatic breast cancer, patients with noncancerous illness, and healthy volunteers. Samples are analyzed for serum glycan biomarkers by matrix-assisted laser desorption/ionization (MALDI) and Fourier transform ion-cyclotron resonance mass spectrometry (FT ICR MS) methods. Blood samples are collected every 3 months for up to 18 months from patients with metastatic breast cancer. Patients without cancer have a single sample collected.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by University of California, Davis.